{
 "id": "xpertsystems/hconc003-sample",
 "owner": "xpertsystems",
 "name": "hconc003-sample",
 "downloads": 11,
 "likes": 0,
 "last_modified": "2026-05-26T20:51:45.000Z",
 "stated_licence": "cc-by-nc-4.0",
 "stated_from": "tag",
 "licence_name": null,
 "licence_link": null,
 "file_licence": null,
 "licence_files": [],
 "sources": [],
 "gated": false,
 "tasks": [
  "tabular-classification",
  "tabular-regression",
  "time-series-forecasting"
 ],
 "citation": "@dataset{xpertsystems_hconc003_2026,\n  title  = {HC-ONC-003: Prostate Cancer Synthetic Cohort with Longitudinal PSA Panel},\n  author = {{XpertSystems.ai}},\n  year   = {2026},\n  version= {1.0.0},\n  url    = {https://huggingface.co/datasets/xpertsystems/hconc003-sample},\n  license= {CC-BY-NC-4.0 (sample); Commercial (full product)},\n  note   = {Calibrated against SEER prostate cancer 2017-2021, NCCN Prostate Cancer Guidelines 2024, AJCC 8th Edition, ISUP 2014 Grade Groups, SEARCH cohort, STAMPEDE (James 2017), CHAARTED (Sweeney 2015), PREVAIL (Beer 2014), COU-AA-301 (de Bono 2011), SPARTAN (Smith 2018), ARAMIS (Fizazi 2019), VISION (Sartor 2021), PROfound (de Bono 2020), PRIAS (Bul 2013), Pritchard 2016 NEJM (BRCA2 prevalence), Antonarakis 2014 NEJM (AR-V7), Abida 2019 JCO (MSI-H), Sanda 2008 NEJM (EPIC-26).}\n}",
 "signal": "restrictive",
 "reason": "The declared licence (cc-by-nc-4.0) is classified as having use restrictions.",
 "revision": "07cf6000d603ee2259f78376d99f73547786469e",
 "stated_evidence": "https://huggingface.co/datasets/xpertsystems/hconc003-sample/blob/07cf6000d603ee2259f78376d99f73547786469e/README.md",
 "file_evidence": "https://huggingface.co/datasets/xpertsystems/hconc003-sample/tree/07cf6000d603ee2259f78376d99f73547786469e",
 "card_nc": false
}